{"id":"83255aa4-bf1b-51fc-8171-af5307bbb689","stable_key":"e69ef6a0-0e23-5eac-aca1-cf333781b962:ino-gdm-2026","predicate":"inconclusive_for","statement":"MiGDM found no significant GDM difference among 43 completers, but early funding-related termination prevented a definitive efficacy test.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"eb5d12f4-3f82-555b-83c4-4b202931ee45","mechanism_event_label":"This small unfinished trial cannot settle whether the supplement works.","subject":{"id":"50afe95c-f542-5511-ba8b-c2ff2b037977","slug":"myo-inositol","display_name":"Myo-inositol","entity_type_key":"small_molecule"},"object":{"id":"a600061a-93c5-525f-aadb-c7a5ab9bcec6","slug":"gdm-incidence","display_name":"Gestational diabetes incidence","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"eb5d12f4-3f82-555b-83c4-4b202931ee45","stable_key":"e69ef6a0-0e23-5eac-aca1-cf333781b962:ino-gdm-2026-event","event_type":"observed_intervention","label":"This small unfinished trial cannot settle whether the supplement works.","description":"MiGDM found no significant GDM difference among 43 completers, but early funding-related termination prevented a definitive efficacy test.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"50afe95c-f542-5511-ba8b-c2ff2b037977","slug":"myo-inositol","display_name":"Myo-inositol","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"a600061a-93c5-525f-aadb-c7a5ab9bcec6","slug":"gdm-incidence","display_name":"Gestational diabetes incidence","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/inositol-research/41742988.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"3b78fed7bce4eedabdbeae7d6e7e562bee8153fa1d0d805b5e96a52004344b29\", \"start_char\": 0, \"end_char\": 3433, \"text_sha256\": \"3b78fed7bce4eedabdbeae7d6e7e562bee8153fa1d0d805b5e96a52004344b29\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"MiGDM double-blind randomized pilot","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Myo-inositol 2 g twice daily versus placebo; stopped early for funding","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Only 67 enrolled and 43 completed versus 640 planned. Severe underpowering makes the result inconclusive, not proof of equivalence.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Inositol research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"inositol","display_name":"Inositol (stereoisomer family)","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"This small unfinished trial cannot settle whether the supplement works.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ino-p41742988] The Effect of Myo-Inositol Supplementation During Pregnancy on Fetal and Maternal Outcomes: Results of the Myo-Inositol for the Prevention of Gestational Diabetes Mellitus (MiGDM) Randomized Double-Blind, Placebo-Controlled Pilot Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41742988/ DOI: 10.7759/cureus.102259","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Pregnant women in Qatar","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"030e11ff-932b-5c77-98b8-6449143c2305","evidence_kind":"source_excerpt","locator":"Lines 1354-1365","start_line":1354,"end_line":1365,"excerpt":"### ino-gdm-2026\nMiGDM found no significant GDM difference among 43 completers, but early funding-related termination prevented a definitive efficacy test.\nCondition category: normal\nnutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: This small unfinished trial cannot settle whether the supplement works.\norganism: Homo sapiens\ntissue_or_cell_type: Pregnant women in Qatar\nexperimental_model: MiGDM double-blind randomized pilot\nlimitations: Only 67 enrolled and 43 completed versus 640 planned. Severe underpowering makes the result inconclusive, not proof of equivalence.\nexposure: Myo-inositol 2 g twice daily versus placebo; stopped early for funding\nevidence_span: {\"source_cache\": \"artifacts/inositol-research/41742988.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"3b78fed7bce4eedabdbeae7d6e7e562bee8153fa1d0d805b5e96a52004344b29\", \"start_char\": 0, \"end_char\": 3433, \"text_sha256\": \"3b78fed7bce4eedabdbeae7d6e7e562bee8153fa1d0d805b5e96a52004344b29\"}\n[ino-p41742988] The Effect of Myo-Inositol Supplementation During Pregnancy on Fetal and Maternal Outcomes: Results of the Myo-Inositol for the Prevention of Gestational Diabetes Mellitus (MiGDM) Randomized Double-Blind, Placebo-Controlled Pilot Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41742988/ DOI: 10.7759/cureus.102259","model_system":"MiGDM double-blind randomized pilot","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ino-p41742988] The Effect of Myo-Inositol Supplementation During Pregnancy on Fetal and Maternal Outcomes: Results of the Myo-Inositol for the Prevention of Gestational Diabetes Mellitus (MiGDM) Randomized Double-Blind, Placebo-Controlled Pilot Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41742988/ DOI: 10.7759/cureus.102259","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d590c659-b774-50e6-9f1d-aff61d5f7c9c","stable_key":"import-e69ef6a0-0e23-5eac-aca1-cf333781b962","title":"Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f7adbcedad647d5f8a3cc9e46bfa515e83c508be9c2a4e9d59c5f5dfb0667d53","revision_id":"a82d187c-60fb-52d1-8482-eadb92860f33","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}